Form 4 Filing for ALNYLAM PHARMACEUTICALS, INC.

This filing details transactions made by David E. I. Pyott, a director at ALNYLAM PHARMACEUTICALS, INC., on June 1, 2026. Pyott exercised stock options for 3,830 shares of common stock at an exercise price of $70.20 per share, which were set to expire on June 3, 2026. Concurrently, he sold 3,830 shares of common stock. The sales were executed under a Rule 10b5-1(c) trading plan. The weighted average selling price for these shares ranged from $297.31 to $302.65. Following these transactions, Pyott directly holds 1,582 shares of common stock. Additionally, the David E I Pyott Trust, of which Pyott is the trustee, holds 27,900 shares of common stock. The shares acquired by the trust are reported as indirect ownership.